Disruptions to Sales and Supply Systems Caused by the Spread of COVID-19
First written in FY2021-Q1. 12 of 14 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2026DroppedAnnual reportThe current securities report contains no separate disclosure that can be identified regarding the risk of interruption to operating and supply systems due to the spread of COVID-19, which had been disclosed previously.
- FY2025-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The Company continues to recognize that there are no new business or other risks and no material changes to existing risks from the previous fiscal year. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The Company continues to recognize that there are no new business or other risks and no material changes to existing risks. - FY2024-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The Company states that there are no new business or other risks or material changes to existing risks, and maintains its previous risk assessment, including that of COVID-19. - FY2023RestatedAnnual report
「Although no crisis has arisen within the Group that would make it difficult to continue normal operations, the Company believes that these risks remain to a certain extent.」
The Company recognizes risks including store closures and the dysfunction of headquarters and process centers due to infectious disease, while stating that no crisis has arisen. - FY2023-Q3RestatedAnnual report
「No new business or other risks arose during the nine months ended [the current third quarter]. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there are no new business or other risks or material changes to existing risks, and maintains its previous risk assessment, including infectious disease risk. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The Company states that there are no new business or other risks or material changes to existing risks, and maintains its previous risk assessment, including that of COVID-19. - FY2023-Q1RestatedAnnual report
「Although the effects of COVID-19 on Japan's economy have been prolonged, signs of a gradual normalization of economic activity have emerged as restrictions on movement have been eased and vaccination has become more widespread.」
The Company describes both the prolonged effects of infectious disease and signs of normalization resulting from eased restrictions on movement and wider vaccination, and maintains its previous assessment of infectious disease risk. - FY2022RestatedAnnual report
「While vaccination against COVID-19 and the development of treatments are progressing and expectations are rising for the normalization of social and economic activity, the number of infections in Japan has repeatedly risen and fallen as variants have spread, and the outlook for convergence remains uncertain. Accordingly, the Group continues to judge the significance of the risks posed by COVID-19 to be high.」
The Company continues to recognize the significance of infectious disease risk as high, while expressing expectations for normalization through vaccines and treatments and citing the spread of variants and fluctuations in infection numbers. - FY2022-Q3RestatedAnnual report
「There were no newly arising business or other risks during the first 3 quarters of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year. The Company will continue to closely monitor the impact of the spread of COVID-19 on the Group's business.」
The Company states that there are no new business risks or material changes to existing risks and continues to monitor the impact of COVID-19. - FY2022-Q1RestatedAnnual report
「The Company will continue to closely monitor the impact of the spread of COVID-19 on the Group's business.」
The Company has stated its policy of continuing to closely monitor the impact of COVID-19 on its business. - FY2021-Q3RestatedAnnual report
「However, if infections spread further and the resulting effects persist, stores could close because of infected employees, headquarters could become nonfunctional, and the product supply system could collapse because of supply chain disruptions, making it impossible to continue normal operations.」
The Company continues to describe store closures, headquarters dysfunction and supply chain disruptions associated with further spread and prolonged effects of infectious disease as business continuity risks. - FY2021-Q2RestatedAnnual report
「However, if infections spread further and the resulting effects persist, stores could close because of infected employees, headquarters could become nonfunctional, and the product supply system could collapse because of supply chain disruptions, making it impossible to continue normal operations.」
The Company continues to describe store closures, headquarters dysfunction and supply chain disruptions associated with further spread and prolonged effects of infectious disease as business continuity risks. - FY2021-Q1First statedAnnual report
「The global pandemic caused by COVID-19 had a significant impact on global production activities. In Japan, efforts to prevent the spread of infection, including school closures and working from home, encouraged people to refrain from nonessential outings. This led to increased demand for meals prepared at home and concentrated demand for daily necessities, while inbound tourism disappeared and demand for leisure and services declined, resulting in significant changes in the environment surrounding the Company. These supply- and demand-side issues have constrained economic activity in every country and region, raising concerns about a global recession exceeding that following the Lehman shock. … However, if infections spread again and the resulting effects persist, stores could close because of infected employees, headquarters could become nonfunctional, and the product supply system could collapse because of supply chain disruptions, making it impossible to continue normal operations.」
The Company describes changes in demand and supply caused by COVID-19 as events that have already occurred, and explicitly identifies store closures, headquarters dysfunction and supply chain disruptions in the event of a second wave and prolonged effects as business continuity risks.